VEGF spliced variants: possible role of anti-angiogenesis therapy. - Wikidata - wikimedia - TriplyDB

VEGF spliced variants: possible role of anti-angiogenesis therapy.

VEGF spliced variants: possible role of anti-angiogenesis therapy.

http://www.wikidata.org/entity/Q35369677

about

Resistance and escape from antiangiogenesis therapy: clinical implications and future strategies Subgroup-specific alternative splicing in medulloblastoma Autocrine functions of VEGF in breast tumor cells: adhesion, survival, migration and invasion.Anti-VEGF agents in metastatic colorectal cancer (mCRC): are they all alike?Analysis of protein isoforms: can we do it better?Oncogenic alternative splicing switches: role in cancer progression and prospects for therapy.Effect of melatonin on tumor growth and angiogenesis in xenograft model of breast cancer.A dedicated microarray for in-depth analysis of pre-mRNA splicing events: application to the study of genes involved in the response to targeted anticancer therapies.Secretion of VEGF-165 has unique characteristics, including shedding from the plasma membrane.Assessing the in vivo efficacy of biologic antiangiogenic therapies.

P2860

Q27016629-99E04BD4-2F14-44F2-9A3A-C62FE36D96D5 Q28260516-36407BED-4130-4FAF-A617-757C19117D19 Q36542090-4D1C867E-6D10-408F-B635-201BBF6485ED Q36936900-7B3F0A7B-EB3B-40FE-B41C-B4D0AA8332AD Q37240124-E050D699-9699-4E4E-A8DC-3402C9A7F0FC Q37304724-FE071678-69A8-4FFA-A718-3C48258D6DDE Q37458674-7AAD8959-1E4D-4BE8-876B-1D26DF2D585F Q37506860-4F2F6394-A294-4D32-87F9-E49C76F1C595 Q37669224-6B161254-6726-42E7-B349-04AD57ADC217 Q38051013-59C7A97E-792B-4E08-B672-8CC7B34367C8

P2860

VEGF spliced variants: possible role of anti-angiogenesis therapy.

http://www.wikidata.org/entity/Q35369677

description

2011 nî lūn-bûn

@nan

2011 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

VEGF spliced variants: possible role of anti-angiogenesis therapy.

@ast

VEGF spliced variants: possible role of anti-angiogenesis therapy.

@en

type

label

VEGF spliced variants: possible role of anti-angiogenesis therapy.

@ast

VEGF spliced variants: possible role of anti-angiogenesis therapy.

@en

prefLabel

VEGF spliced variants: possible role of anti-angiogenesis therapy.

@ast

VEGF spliced variants: possible role of anti-angiogenesis therapy.

@en

P1433

Q35369677-98409A5A-D182-47A4-B3B7-7EC0967CFE1A

P1476

Q35369677-C452D4C4-C269-4F98-B3DA-DC691C6E2167

P2093

Q35369677-1AAAECD2-C60A-4CBB-9338-D7F3CE496BB1

Q35369677-234D7A77-679F-4105-9FF8-AD70914BF0F6

Q35369677-4EBA460D-E01F-4B5D-B1A1-0E5E425AC89B

P2860

Q35369677-03ABEEDB-BCD3-4CC3-A8FB-778159DF826A

Q35369677-05870350-8987-479E-93AA-57904F3DA9CB

Q35369677-074C381C-E902-431B-9BF5-6DDE46089402

Q35369677-0B82A79A-7BB3-4AAF-8263-D4F79E306DA2

Q35369677-12B58C6A-201A-45D9-819E-9004EE10A3DB

Q35369677-15E4977D-2991-4AE0-92B9-E66B7DC8F3B4

Q35369677-1D4B0DD6-8567-4DFF-B8EE-15683087CD12

Q35369677-1EFB0BEF-6306-4695-B11E-6045767069B1

Q35369677-231EDDEE-B2BF-40A5-8418-7C2941C13D99

Q35369677-265B193E-0278-45D2-BF58-BC009F3759B1

P304

Q35369677-C21027D0-0C84-49B5-BA97-0E6D6A347231

P31

Q35369677-54A779E5-9EE9-4860-BF44-4FF79D49D8FD

P356

Q35369677-7380C6A5-9E84-4B59-9D1F-DA28830CBE74

P478

Q35369677-18B935EB-599E-46F5-95A9-E361307BC8F9

P577

Q35369677-36A6FFDB-AD75-41A3-8248-A51D2F3F00E4

P5875

Q35369677-DE6FA434-B08F-439E-B6E8-49DE4152A190

P698

Q35369677-D3BADF77-9A5D-4892-BABD-7F89DCE5C016

P932

Q35369677-5E43193D-392B-47A2-8AF7-D80EC990E721

P356

P1433

Journal of Nucleic Acids

P1476

VEGF spliced variants: possible role of anti-angiogenesis therapy.

@en

P2093

Caroline Hilmi

http://www.w3.org/2001/XMLSchema#string

Gilles Pagès

http://www.w3.org/2001/XMLSchema#string

Mélanie Guyot

http://www.w3.org/2001/XMLSchema#string

P2860

Signaling properties of VEGF receptor-1 and -2 homo- and heterodimers

Role of PlGF in the intra- and intermolecular cross talk between the VEGF receptors Flt1 and Flk1

VEGF and the Fab fragment of a humanized neutralizing antibody: crystal structure of the complex at 2.4 A resolution and mutational analysis of the interface

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

Vascular endothelial growth factor mediates intracrine survival in human breast carcinoma cells through internally expressed VEGFR1/FLT1

Regulation of vascular endothelial growth factor (VEGF) splicing from pro-angiogenic to anti-angiogenic isoforms: a novel therapeutic strategy for angiogenesis

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

P304

162692

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1155/2012/162692

http://www.w3.org/2001/XMLSchema#string

P478

2012

http://www.w3.org/2001/XMLSchema#string

P577

2011-10-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51732194

http://www.w3.org/2001/XMLSchema#string

P698

22013509

http://www.w3.org/2001/XMLSchema#string

P932

3195439

http://www.w3.org/2001/XMLSchema#string